Molecular Partners moves MP0712 to higher dose in Phase 1/2a study
The company reported H1 2026 results, a new CD70 radio target for kidney cancer, and cash of CHF 67.9 million expected to last into late 2027.
SEC filing
Latest
2 stories
Tuesday, August 25
Monday, July 20
Molecular Partners reports progress in Phase 2 TACTIC trial of MP0317 for cholangiocarcinoma
Nine trial sites are activated and treating patients in the randomized study, with a data update expected in 2027 and completion in 2028.
SEC filing